Castle Biosciences, Inc. (CSTL)

NASDAQ: CSTL · IEX Real-Time Price · USD
19.48
-0.23 (-1.17%)
At close: May 16, 2022 4:00 PM
20.00
0.52 (2.67%)
After-hours:May 16, 2022 6:15 PM EDT
Market Cap511.56M
Revenue (ttm)98.12M
Net Income (ttm)-51.64M
Shares Out26.26M
EPS (ttm)-1.25
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume303,730
Open19.54
Previous Close19.71
Day's Range19.22 - 20.42
52-Week Range17.01 - 78.92
Beta0.58
AnalystsBuy
Price Target66.59 (+241.8%)
Earnings DateMay 9, 2022

About CSTL

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test...

IndustryBiotechnology
IPO DateJul 25, 2019
Employees342
Stock ExchangeNASDAQ
Ticker SymbolCSTL
Full Company Profile

Financial Performance

In 2021, CSTL's revenue was $94.09 million, an increase of 50.18% compared to the previous year's $62.65 million. Losses were -$31.29 million, 204.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for CSTL stock is "Buy." The 12-month stock price forecast is 66.59, which is an increase of 241.84% from the latest price.

Price Target
$66.59
(241.84% upside)
Analyst Consensus: Buy
Stock Forecasts

News

7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years

Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF.

5 days ago - InvestorPlace

Castle Biosciences Collaborates with The Sun Bus to Provide Free Skin Cancer Screenings

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences has once again teamed up with The Sun Bus as a national sponsor of their mobile clinic.

6 days ago - Business Wire

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -19.40% and 6.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Castle Biosciences Reports First Quarter 2022 Results

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the f...

1 week ago - Business Wire

Castle Biosciences Recognizes Skin Cancer Awareness Month through Its Support of Patient-Focused Initiatives

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced that it will collaborate with the Melanoma Research Foundation and The Skin Cancer Foundation during Skin Cancer Awareness Month.

1 week ago - Business Wire

Castle Biosciences Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer P...

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced that its current U.S. Federal Supply Schedule contract with the Veterans Health Administration was expanded as of April 15, 2022.

2 weeks ago - Business Wire

Data from Independent, Pooled Analysis Show Significantly Improved Risk Predictions Over Clinical Variables for Tissu...

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BarrettsEsophagus--Castle announced an independent, peer-reviewed article in Clinical Gastroenterology and Hepatology for its TissueCypher® Barrett's Esoph...

2 weeks ago - Business Wire

Castle Biosciences Completes Acquisition of AltheaDx

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences announced that it has completed its acquisition of AltheaDx, Inc.

2 weeks ago - Business Wire

Castle Biosciences to Release First Quarter 2022 Financial Results and Host Conference Call on Monday, May 9

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences will release its financial results for the first quarter ended March 31, 2022, after the close of market on Monday, May 9, 2022.

3 weeks ago - Business Wire

Expanded SEER Registries Dataset Shows Improved Survival for DecisionDx®-Melanoma Tested Patients Compared to Unteste...

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced new data from a recent study showing patients tested with DecisionDx®-Melanoma had improved survival compared to untested patients.

3 weeks ago - Business Wire

Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present data on its skin cancer gene expression profile tests at the 18th European Association of Dermato Oncology (EADO) Congress.

3 weeks ago - Business Wire

Castle Biosciences Presents Data on Its Inflammatory Skin Disease Pipeline Test at the 4th Annual Revolutionizing Ato...

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced a poster presentation on its inflammatory skin disease pipeline test at the 4th Annual Revolutionizing Atopic Dermatitis Conference.

4 weeks ago - Business Wire

Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences will present a company overview at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 3:00 p.m. ET.

1 month ago - Business Wire

Castle Biosciences to Acquire AltheaDx

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #MA--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a d...

1 month ago - Business Wire

Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett's Esophagus T...

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BarrettsEsophagus--Castle Biosciences announced that the Centers for Medicare & Medicaid Services granted ADLT status for the TissueCypher® Barrett's Esoph...

1 month ago - Business Wire

Data to be Presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting Demonstrate Ability of Decision...

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present data on two of its GEP tests for skin cancer at the 2022 American Academy of Dermatology (AAD) Annual Meeting, March 25-29, 2022.

1 month ago - Business Wire

Independent Data Presented at Society for Surgical Oncology Conference Demonstrated DecisionDx®-Melanoma Outperforms ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will share new data on DecisionDx®-Melanoma and i31-SLNB at the SSO 2022 International Conference on Surgical Cancer Care, March 9-12.

2 months ago - Business Wire

Castle Biosciences to Present at Upcoming Investor Conferences

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences is scheduled to present a company overview at upcoming investor conferences.

2 months ago - Business Wire

Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 41.86% and 6.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Castle Biosciences Reports Fourth Quarter and Full-Year 2021 Results

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BarrettsEsophagus--Castle today announced its financial results for the fourth quarter and twelve months ended Dec. 31, 2021.

2 months ago - Business Wire

Earnings Preview: Castle Biosciences, Inc. (CSTL) Q4 Earnings Expected to Decline

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday,...

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will release its financial results for the fourth quarter and year-ended Dec. 31, 2021, after the close of market on Monday, Feb. 28, 2022.

3 months ago - Business Wire

Castle Biosciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle is scheduled to present a company overview at the 11th Annual SVB Leerink Global Healthcare Conference on Feb. 17, 2022, at 3 p.m. ET.

3 months ago - Business Wire

Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEE...

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced a collaboration with the NCI to link DecisionDx®-Melanoma testing data with data from the SEER Program's registries.

3 months ago - Business Wire

Castle Biosciences Named a Winner of the 2022 Top Workplaces USA Award

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BarretsEsophagus--Castle Biosciences announced that it has received a 2022 Top Workplaces USA award from Energage.

3 months ago - Business Wire